Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.92
+0.17 (2.87%)
Nov 21, 2024, 11:52 AM EST - Market open
Abeona Therapeutics Revenue
In the year 2023, Abeona Therapeutics had annual revenue of $3.50M with 147.52% growth.
Revenue (ttm)
$3.50M
Revenue Growth
+147.52%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
84
Market Cap
257.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Zynex | 193.67M |
Anika Therapeutics | 164.17M |
Poseida Therapeutics | 150.86M |
Lifecore Biomedical | 128.44M |
Eton Pharmaceuticals | 34.68M |
Fate Therapeutics | 13.45M |
Ocugen | 4.70M |
ABEO News
- 7 days ago - Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 9 days ago - Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 17 days ago - Abeona Therapeutics® Announces Participation in November Investor Conferences - GlobeNewsWire
- 20 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration - GlobeNewsWire
- 7 weeks ago - Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy - Seeking Alpha
- 2 months ago - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - GlobeNewsWire